Skip Navigation

Continuing Education in Anaesthesia, Critical Care & Pain 2004 4(6):207-209; doi:10.1093/bjaceaccp/mkh056
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Continuing Education in Anaesthesia, Critical Care & Pain | Volume 4 Number 6 2004 © The Board of Management and Trustees of the British Journal of Anaesthesia 2004

Multiple Choice Questions

The first 10% of the full text of this article appears below.

128. Glycoprotein IIb/IIIa inhibitors:
  1. Reduce platelet aggregation.
  2. Improve outcome with thrombolysis.
  3. Reduce the risk of non-fatal MI in NSTEMI patients undergoing coronary angioplasty.
  4. Can only be administered on a single occasion to any patient.
  5. Need to be reversed before major surgery.

129. The troponins:
  1. Have a greater sensitivity than CK-MB in diagnosis of MI.
  2. May be detected in serum 5 days after infarction.
  3. When detected in serum invariably reflect irreparable myocardial damage.
  4. Will be significantly elevated in serum within 1 h of MI.
  5. Have a prognostic role in critical illness.

130. Regarding reperfusion therapy:
  1. rt-PA is invariably superior to streptokinase.
  2. Thrombolysis is indicated within 24 h of presentation.
  3. PTCA is only indicated in STEMI.
  4. PTCA is a superior treatment to thrombolysis in STEMI.
  5. PTCA is contraindicated in cardiogenic shock.

131. The following . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?